Skip to content

Phibro Animal Health

US · PAHC #2966 by market cap Listed 1970
33.29 -0.79 -2.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 3.50 In line with history 60th percentile
5-year average 3.29 · #48 of 68 in Drug Manufacturers - Specialty & Generic
P/E ratio 14.39 Cheap vs history 20th percentile
5-year average 39.11 · forward 11.10 · #9 of 25 in Drug Manufacturers - Specialty & Generic
P/S ratio 0.95 Expensive vs history 74th percentile
5-year average 0.83 · forward 0.92 · #20 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Phibro Animal Health (PAHC) 1.35B 13.32 3.24 1.44%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value44.41 Economic moatNone UncertaintyHigh

Trading 33.4% below Morningstar's fair value estimate.

Fair value

Phibro Animal Health Corp earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 19% discount to our quantitative fair value estimate of $44.41 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's profitability increases our valuation estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's earnings yield of 9.9% lies in the top 30% globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are cheap.

The firm's solid growth is an additional encouraging factor. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. The firm's revenue 3-year growth of 18.7%, for example, sits in the top 20% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which further promotes our favorable price/fair value ratio.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Phibro Animal Health discussion 0 comments

Add a comment